Global Information Inc. would like to present a new market research report, "Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" by GlobalData.
The Insulin Delivery Devices Market is Set to Grow at a CAGR of 6% to Reach $11 Billion by 2017
GlobalData estimated the global insulin delivery devices market at $7.4 billion in 2010. Driven by the significant increase in prevalence of diabetes; the availability of reimbursement for insulin delivery devices and positive clinical outcomes from studies, the market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% to exceed $11 billion in 2017.
The US is the largest insulin delivery devices market. The US insulin delivery devices market was valued at $2.8 billion in 2010 and is expected to grow at a CAGR of 6% to reach $4.2 billion by 2017. The growth will be fuelled by a number of factors, such as the increase in the incidence of diabetes among all ages, higher market penetration of insulin pumps and the availability of reimbursement.
Insulin pumps are used more commonly in the US than in European countries. According to an article published in the Journal of Diabetes Science and Technology in May 2010, entitled "Evolution of Diabetes Insulin Delivery Devices", insulin pumps are used more in the US for insulin delivery, whereas in Europe, insulin pens are more commonly used. According to Juvenile Diabetes Research Federation (JDRF) estimates, about 400,000 people in the US with type 1 diabetes use insulin pumps.
Medtronic is the leading player in the global insulin delivery devices market with a share of about 20% in 2010, followed by Novo Nordisk and Sanofi with a share of 16% and 15% respectively.
The leadership of Medtronic can be attributed to its Research and Development (R&D) capabilities, extensive marketing channels and strong brand image in the insulin pumps market. Over the years, Medtronic has developed and introduced diabetes solutions for both healthcare professionals and patients, including the worlds first integrated insulin pump and Continuous Glucose Monitor (CGM) system. Medtronic Diabetes has invested over $100m in the past decade on R&D, allowing it to gain a competitive advantage and drive its product portfolio, ultimately enabling it to gain larger market share.
Increasing Incidence of Diabetes, Especially Increase in the Incidence of Childhood Insulin Dependent Diabetes, to Boost the Market Growth
Many studies suggest that the incidence of diabetes in children under the age of 18 years is increasing rapidly. According to a study conducted by EURODIAB and published in The Lancet in June 2009 prevalence of type 1 diabetes among children younger than 15 years of age in Europe is projected to increase from 94,000 in 2005 to 160,000 in 2020. The study also found the historical annual increase in the incidence of diabetes among children from 1989 to 2003. The overall annual increase in the incidence of type 1 diabetes among children was 3.9%. The highest increase in the incidence rate was found among children aged 0-4 years
Researchers have found a number of reasons for the increasing incidence of diabetes among children such as increasing obesity, irregular dietary habits and lower vitamin D intake among others. Being born to a diabetic mother also increases the risk of getting diabetes among children.
According to estimates from the International Diabetes Federation (IDF), 366 million people globally in 2011 suffered from diabetes. This is expected to rise to 552 million by 2030. The IDF also estimates that 183 million people globally or 50% of diabetics are undiagnosed. Globally, 4.6 million people died as a result of diabetes in 2011 and $465 billion was spent on diabetes healthcare expenditure. About 80% of people suffering from diabetes live in low or middle-income countries. The IDF estimates that 78,000 children globally develop diabetes every year, a figure which is increasing.
According to the IDF, 23.7 million people suffered from diabetes in the US in 2011. The IDF also estimates that about 180,000 people died as a result of diabetes in the US in 2011, which is the highest in the world. The IDF estimates that the prevalence of diabetes in India was 8.3% in 2011, affecting over 61 million people. About 5.7% of people were suspected to be suffering from pre-diabetes in 2010. At the current rate, the number of people suffering from diabetes in India will reach 101.2 million in 2030.
The IDF estimates that diabetes prevalence in China was 9.3% in 2011, translating to over 90 million people in the same year. It is estimated that 60.7% of people are undiagnosed and that about 6.8% of people in China were suspected to be suffering from pre-diabetes in 2010. At the current rate, the number of people suffering from diabetes in China is expected to rise to 129.7 million by 2030.